Neuro-ophthalmologic Manifestations of Primary Headache Disorders

REFERENCES

• Burton W N, Conti D J, Chen C Y, Schultz A B, Edington D W. The economic burden of lost productivity due to migraine headache: a specific worksite analysis. J Occup Environ Med 2002; 44(6)523–9
   PubMedGoogle Scholar
• Bensenor I M. The huge burden of minor symptoms: the case of migraine headaches. Sao Paulo Med J 2005; 123(6)259–60
   PubMedGoogle Scholar
• Leonardi M, Steiner T J, Scher A T, Lipton R B. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005; 6(6)429–40
   PubMedGoogle Scholar
• Kobak K A, Katzelnick D J, Sands G, King M, Greist J J, Dominski M. Prevalence and burden of illness of migraine in managed care patients. J Manag Care Pharm 2005; 11(2)124–36
   PubMedGoogle Scholar
• Brixner D I. Prevalence and burden of migraine and the impact on managed care. Manag Care 2007; 16(7 Suppl 7)2–3, discussion 15–7
   PubMedGoogle Scholar
• Hawkins K, Wang S, Rupnow M F. Indirect cost burden of migraine in the United States. J Occup Environ Med 2007; 49(4)368–74
   PubMed Web of Science ®Google Scholar
• Lipton R B, Bigal M E, Diamond M, Freitag F, Reed M L, Stewart W F. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68(5)343–9
   PubMed Web of Science ®Google Scholar
• Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007; 27(3)193–210
   PubMed Web of Science ®Google Scholar
• Lipton R B, Stewart W F, Diamond S, Diamond M L, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41(7)646–57
   PubMed Web of Science ®Google Scholar
• Welch K M, Nagesh V, Aurora S K, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?. Headache 2001; 41(7)629–37
   PubMed Web of Science ®Google Scholar
• Lipton R B, Stewart W F, Von Korff M. The burden of migraine. A review of cost to society. Pharmacoeconomics 1994; 6(3)215–21
   PubMedGoogle Scholar
• Lipton R B, Stewart W F, von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology 1997; 48(3 Suppl 3)S4–9
   PubMedGoogle Scholar
• The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24(Suppl 1)9–160
   PubMed Web of Science ®Google Scholar
• World Health Organization. The World Health Report 2001: Mental Health, New Understanding New Hope
   Google Scholar
• Lipton R B, Bigal M E. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005; 45(Suppl 1)S3–S13
   PubMed Web of Science ®Google Scholar
• Domitrz I. [Migraine with visual aura: visual aura pictured by the patient]. Neurol Neurochir Pol 2007; 41(2)181–7
   PubMedGoogle Scholar
• Evans R W, Rolak L A. The Alice in Wonderland Syndrome. Headache 2004; 44(6)624–5
   PubMedGoogle Scholar
• Todd J. The syndrome of Alice in Wonderland. Can Med Assoc J 1955; 73(9)701–4
   PubMedGoogle Scholar
• Vincent M B, Hadjikhani N. Migraine aura and related phenomena: beyond scotomata and scintillations. Cephalalgia 2007; 27(12)1368–77
   PubMedGoogle Scholar
• Appleton R, Farrell K, Buncic J R, Hill A. Amaurosis fugax in teenagers. A migraine variant. Am J Dis Child 1988; 142(3)331–3
   PubMedGoogle Scholar
• Grosberg B M, Solomon S, Friedman D I, Lipton R B. Retinal migraine reappraised. Cephalalgia 2006; 26(11)1275–86
   PubMedGoogle Scholar
• Hill D L, Daroff R B, Ducros A, Newman N J, Biousse V. Most cases labeled as “retinal migraine” are not migraine. J Neuroophthalmol 2007; 27(1)3–8
   PubMed Web of Science ®Google Scholar
• Ekbom K, Waldenlind E. Cluster headache: the history of the Cluster Club and a review of recent clinical research. Funct Neurol 2004; 19(2)73–81
   PubMedGoogle Scholar
• Mishra N K, Cereda C, Carota A. Lifetime Basilar Migraine: A Pontine Syndrome?. Headache 2007
   Google Scholar
• Kunkel R S. Migraine aura without headache: benign, but a diagnosis of exclusion. Cleve Clin J Med 2005; 72(6)529–34
   PubMedGoogle Scholar
• Ziegler D K, Hassanein R S. Specific headache phenomena: their frequency and coincidence. Headache 1990; 30(3)152–6
   PubMedGoogle Scholar
• Luda E, Bo E, Sicuro L, Comitangelo R, Campana M. Sustained visual aura: a totally new variation of migraine. Headache 1991; 31(9)582–3
   PubMedGoogle Scholar
• Migrainous cerebral infarction. Br Med J 1977; 1(6060)532–3
   Google Scholar
• Agostoni E, Aliprandi A. The complications of migraine with aura. Neurol Sci 2006; 27(Suppl 2)S91–5
   PubMedGoogle Scholar
• Tourbah A, Mas J L, Baron J C, Bousser M G. Complicated migraine, migrainous infarction … or what?. Headache 1988; 28(10)689
   PubMedGoogle Scholar
• Fernandez D M, Hand C K, Sweeney B J, Parfrey N A. A novel ATP1A2 gene mutation in an Irish familial hemiplegic migraine kindred. Headache 2008; 48(1)101–8
   PubMedGoogle Scholar
• Battistini S, Stenirri S, Piatti M, et al. A new CACNA1A gene mutation in acetazolamide–responsive familial hemiplegic migraine and ataxia. Neurology 1999; 53(1)38–43
   PubMed Web of Science ®Google Scholar
• Black D F. Sporadic and familial hemiplegic migraine: diagnosis and treatment. Semin Neurol 2006; 26(2)208–16
   PubMedGoogle Scholar
• Blostein R, Segall L, Gargus J J. [ATP1A2: a key player in familial hemiplegic migraine]. Med Sci (Paris) 2006; 22(4)341–3
   PubMedGoogle Scholar
• Castro M J, Nunes B, de Vries B, et al. Two novel functional mutations in the Na+,K+-ATPase alpha2–subunit ATP1A2 gene in patients with familial hemiplegic migraine and associated neurological phenotypes. Clin Genet 2008; 73(1)37–43
   PubMedGoogle Scholar
• Castro M J, Stam A H, Lemos C, et al. Recurrent ATP1A2 mutations in Portuguese families with familial hemiplegic migraine. J Hum Genet 2007; 52(12)990–8
   PubMedGoogle Scholar
• Kraus R L, Sinnegger M J, Koschak A, et al. Three new familial hemiplegic migraine mutants affect P/Q-type Ca(2+) channel kinetics. J Biol Chem 2000; 275(13)9239–43
   PubMedGoogle Scholar
• Ophoff R A, Terwindt G M, Vergouwe M N, Frants R R, Ferrari M D. Wolff Award 1997. Involvement of a Ca2+ channel gene in familial hemiplegic migraine and migraine with and without aura. Dutch Migraine Genetics Research Group. Headache 1997; 37(8)479–85
   PubMedGoogle Scholar
• Vanmolkot K R, Kors E E, Turk U, et al. Two de novo mutations in the Na,K-ATPase gene ATP1A2 associated with pure familial hemiplegic migraine. Eur J Hum Genet 2006; 14(5)555–60
   PubMedGoogle Scholar
• Mark A S, Casselman J, Brown D, et al. Ophthalmoplegic migraine: reversible enhancement and thickening of the cisternal segment of the oculomotor nerve on contrast-enhanced MR images. AJNR Am J Neuroradiol 1998; 19(10)1887–91
   PubMed Web of Science ®Google Scholar
• Goadsby P J. Migraine pathophysiology. Headache 2005; 45(Suppl 1)S14–24
   Google Scholar
• Welch K M. Concepts of migraine headache pathogenesis: insights into mechanisms of chronicity and new drug targets. Neurol Sci 2003; 24(Suppl 2)S149–53
   PubMedGoogle Scholar
• Aurora S K. Pathophysiology of migraine headache. Curr Pain Headache Rep 2001; 5(2)179–82
   PubMedGoogle Scholar
• Aurora S K, Welch K M. Migraine: imaging the aura. Curr Opin Neurol 2000; 13(3)273–6
   PubMedGoogle Scholar
• Olsen T S. Pathophysiology of the migraine aura: the spreading depression theory. Brain 1995; 118: 307–8, (Pt 1)
   PubMedGoogle Scholar
• Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994; 117: 199–210, (Pt 1)
   PubMed Web of Science ®Google Scholar
• Silberstein S D. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55(6)754–62
   PubMed Web of Science ®Google Scholar
• Porta M, Camerlingo M. Headache and botulinum toxin. J Headache Pain 2005; 6(4)325–7
   PubMedGoogle Scholar
• Aurora S K, Gawel M, Brandes J L, Pokta S, Vandenburgh A M. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007; 47(4)486–99
   PubMed Web of Science ®Google Scholar
• Elkind A H, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006; 7(10)688–96
   PubMed Web of Science ®Google Scholar
• Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt I W, Frese A. Botulinum toxin A in the prophylactic treatment of migraine–a randomized, double-blind, placebo-controlled study. Cephalalgia 2004; 24(10)838–43
   PubMedGoogle Scholar
• Relja M, Poole A C, Schoenen J, Pascual J, Lei X, Thompson C. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007; 27(6)492–503
   PubMed Web of Science ®Google Scholar
• Saper J R, Mathew N T, Loder E W, DeGryse R, Van Denburgh A M. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med 2007; 8(6)478–85
   PubMed Web of Science ®Google Scholar
• Binder W J, Brin M F, Blitzer A, Schoenrock L D, Pogoda J M. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000; 123(6)669–76
   PubMed Web of Science ®Google Scholar
• Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000; 40(6)445–50
   PubMed Web of Science ®Google Scholar
• Athwal B S, Lennox G G. Acetazolamide responsiveness in familial hemiplegic migraine. Ann Neurol 1996; 40(5)820–1
   PubMedGoogle Scholar
• Haan J, Sluis P, Sluis L H, Ferrari M D. Acetazolamide treatment for migraine aura status. Neurology 2000; 55(10)1588–9
   PubMedGoogle Scholar
• Rothrock J F. Successful treatment of persistent migraine aura with divalproex sodium. Neurology 1997; 48(1)261–2
   PubMedGoogle Scholar
• Cohen A S, Matharu M S, Goadsby P J. Trigeminal autonomic cephalalgias: current and future treatments. Headache 2007; 47(6)969–80
   PubMedGoogle Scholar
• Goadsby P J. Trigeminal autonomic cephalalgias. Pathophysiology and classification. Rev Neurol (Paris) 2005; 161(6–7)692–5
   PubMedGoogle Scholar
• Sprenger T, Boecker H, Tolle T R, Bussone G, May A, Leone M. Specific hypothalamic activation during a spontaneous cluster headache attack. Neurology 2004; 62(3)516–7
   PubMedGoogle Scholar
• Horton B T. Histaminic cephalalgia; guest editorial. J Am Med Assoc 1956; 160(6)468–9
   PubMedGoogle Scholar
• Roberts S E. Histaminic cephalalgia (suicide headache). Laryngoscope 1954; 64(1)35–44
   PubMedGoogle Scholar
• Kudrow L. Cluster headache. Cephalalgia 1992; 12(3)128
   PubMedGoogle Scholar
• Kudrow L. Cluster headache. A review. Clin J Pain 1989; 5(1)29–38
   PubMedGoogle Scholar
• Russell M B, Andersson P G, Thomsen L L, Iselius L. Cluster headache is an autosomal dominantly inherited disorder in some families: a complex segregation analysis. J Med Genet 1995; 32(12)954–6
   PubMed Web of Science ®Google Scholar
• Kudrow L, Kudrow D B. Inheritance of cluster headache and its possible link to migraine. Headache 1994; 34(7)400–7
   PubMedGoogle Scholar
• May A, Bahra A, Buchel C, Frackowiak R S, Goadsby P J. Hypothalamic activation in cluster headache attacks. Lancet 1998; 352(9124)275–8
   PubMed Web of Science ®Google Scholar
• Goadsby P J. Evidence for hypothalamic activation in cluster headache. Ital J Neurol Sci 1999; 20(2 Suppl)S80–3
   Google Scholar
• Green A L, Owen S L, Davies P, Moir L, Aziz T Z. Deep brain stimulation for neuropathic cephalalgia. Cephalalgia 2006; 26(5)561–7
   PubMedGoogle Scholar
• May A. Cluster headache: pathogenesis, diagnosis, and management. Lancet 2005; 366(9488)843–55
   PubMedGoogle Scholar
• Fogan L. Treatment of cluster headache. A double-blind comparison of oxygen v air inhalation. Arch Neurol 1985; 42(4)362–3
   PubMedGoogle Scholar
• van Vliet J A, Bahra A, Martin V, et al. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. Neurology 2003; 60(4)630–3
   PubMed Web of Science ®Google Scholar
• Cittadini E, May A, Straube A, Evers S, Bussone G, Goadsby P J. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. Arch Neurol 2006; 63(11)1537–42
   PubMedGoogle Scholar
• Rapoport A M, Mathew N T, Silberstein S D, et al. Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study. Neurology 2007; 69(9)821–6
   PubMed Web of Science ®Google Scholar
• Matharu M S, Levy M J, Meeran K, Goadsby P J. Subcutaneous octreotide in cluster headache: randomized placebo-controlled double-blind crossover study. Ann Neurol 2004; 56(4)488–94
   PubMed Web of Science ®Google Scholar
• Magnoux E, Zlotnik G. Outpatient intravenous dihydroergotamine for refractory cluster headache. Headache 2004; 44(3)249–55
   PubMedGoogle Scholar
• Andersson P G, Jespersen L T. Dihydroergotamine nasal spray in the treatment of attacks of cluster headache. A double-blind trial versus placebo. Cephalalgia 1986; 6(1)51–4
   PubMedGoogle Scholar
• Leone M, D'Amico D, Frediani F, et al. Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology 2000; 54(6)1382–5
   PubMed Web of Science ®Google Scholar
• May A, Leone M, Afra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 2006; 13(10)1066–77
   PubMed Web of Science ®Google Scholar
• Franzini A, Ferroli P, Leone M, Broggi G. Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series. Neurosurgery 2003; 52(5)1095–9, discussion 9–101
   PubMedGoogle Scholar
• Leone M, Franzini A, Felisati G, et al. Deep brain stimulation and cluster headache. Neurol Sci 2005; 26(Suppl 2)s138–9
   Google Scholar
• Ambrosini A. Occipital nerve stimulation for intractable cluster headache. Lancet 2007; 369(9567)1063–5
   PubMedGoogle Scholar
• Burns B, Watkins L, Goadsby P J. Treatment of medically intractable cluster headache by occipital nerve stimulation: long-term follow-up of eight patients. Lancet 2007; 369(9567)1099–106
   PubMed Web of Science ®Google Scholar
• Busch V, Jakob W, Juergens T, Schulte-Mattler W, Kaube H, May A. Occipital nerve blockade in chronic cluster headache patients and functional connectivity between trigeminal and occipital nerves. Cephalalgia 2007; 27(11)1206–14
   PubMed Web of Science ®Google Scholar
• Leone M, Franzini A, Cecchini A P, Broggi G, Bussone G. Stimulation of occipital nerve for drug-resistant chronic cluster headache. Lancet Neurol 2007; 6(4)289–91
   PubMedGoogle Scholar
• Magis D, Allena M, Bolla M, De Pasqua V, Remacle J M, Schoenen J. Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study. Lancet Neurol 2007; 6(4)314–21
   PubMed Web of Science ®Google Scholar
• Schwedt T J, Dodick D W, Trentman T L, Zimmerman R S. Occipital nerve stimulation for chronic cluster headache and hemicrania continua: pain relief and persistence of autonomic features. Cephalalgia 2006; 26(8)1025–7
   PubMedGoogle Scholar
• Sjaastad O, Kruszewski P. Trigeminal neuralgia and “SUNCT” syndrome: similarities and differences in the clinical pictures. An overview. Funct Neurol 1992; 7(2)103–7
   PubMedGoogle Scholar
• Sjaastad O, Zhao J M, Kruszewski P, Stovner L J. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection, tearing, etc. (SUNCT): III. Another Norwegian case. Headache 1991; 31(3)175–7
   PubMedGoogle Scholar
• Pareja J A, Sjaastad O. SUNCT syndrome. A clinical review. Headache 1997; 37(4)195–202
   PubMedGoogle Scholar
• Pareja J A, Shen J M, Kruszewski P, Caballero V, Pamo M, Sjaastad O. SUNCT syndrome: duration, frequency, and temporal distribution of attacks. Headache 1996; 36(3)161–5
   PubMedGoogle Scholar
• Cohen A S. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing. Cephalalgia 2007; 27(7)824–32
   PubMedGoogle Scholar
• Cohen A S, Matharu M S, Goadsby P J. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) or cranial autonomic features (SUNA)–a prospective clinical study of SUNCT and SUNA. Brain 2006; 129: 2746–60, (Pt 10)
   PubMed Web of Science ®Google Scholar
• Volcy M, Tepper S J, Rapoport A M, Sheftell F D, Bigal M E. Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)–a case report. Cephalalgia 2005; 25(6)470–2
   PubMedGoogle Scholar
• Goadsby P J, Cohen A S, Matharu M S. Trigeminal autonomic cephalalgias: diagnosis and treatment. Curr Neurol Neurosci Rep 2007; 7(2)117–25
   PubMedGoogle Scholar
• May A, Bahra A, Buchel C, Turner R, Goadsby P J. Functional magnetic resonance imaging in spontaneous attacks of SUNCT: short-lasting neuralgiform headache with conjunctival injection and tearing. Ann Neurol 1999; 46(5)791–4
   PubMedGoogle Scholar
• Sprenger T, Valet M, Platzer S, Pfaffenrath V, Steude U, Tolle T R. SUNCT: bilateral hypothalamic activation during headache attacks and resolving of symptoms after trigeminal decompression. Pain 2005; 113(3)422–6
   PubMedGoogle Scholar
• Sjaastad O. Chronic paroxysmal hemicrania, hemicrania continua and SUNCT: the fate of the three first described cases. J Headache Pain 2006; 7(3)151–6
   PubMedGoogle Scholar
• Pareja J A, Caminero A B, Sjaastad O. SUNCT Syndrome: diagnosis and treatment. CNS Drugs 2002; 16(6)373–83
   PubMed Web of Science ®Google Scholar
• Leone M, Franzini A, D'Andrea G, Broggi G, Casucci G, Bussone G. Deep brain stimulation to relieve drug-resistant SUNCT. Ann Neurol 2005; 57(6)924–7
   PubMedGoogle Scholar
• Sprenger T, Valet M, Hammes M, et al. Hypothalamic activation in trigeminal autonomic cephalgia: functional imaging of an atypical case. Cephalalgia 2004; 24(9)753–7
   PubMedGoogle Scholar
• Sjaastad O, Dale I. A new (?) Clinical headache entity “chronic paroxysmal hemicrania” 2. Acta Neurol Scand 1976; 54(2)140–59
   PubMedGoogle Scholar
• Price R W, Posner J B. Chronic paroxysmal hemicrania: a disabling headache syndrome responding to indomethacin. Ann Neurol 1978; 3(2)183–4
   PubMedGoogle Scholar
• Jotkowitz S. Chronic paroxysmal hemicrania and cluster. Ann Neurol 1978; 4(4)389
   PubMedGoogle Scholar
• Antonaci F, Pareja J A, Caminero A B, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: the ‘indotest.’. Headache 1998; 38(2)122–8
   PubMedGoogle Scholar
• Pareja J A, Vincent M, Antonaci F, Sjaastad O. Hemicrania continua: diagnostic criteria and nosologic status. Cephalalgia 2001; 21(9)874–7
   PubMedGoogle Scholar